Treating tumors using implants comprising combinations of allogeneic cells
AssigneeThe Regents of the University of California
InventorsJames A. Thompson, Gale A. Granger
Life of this patent
Estimating the term…
Abstract
This invention provides methods and compositions for treating tumors by implanting near the tumor an alloactivated cell population. The cell population is made up of a plurality of third-party donor cells that have been cultured together ex vivo, and harvested near the time of peak cytokine secretion. Once placed in the tumor bed, the alloactivated cells recruit active participation of the host, which then reacts against the tumor and provides a level of ongoing protection. Employing multiple third party donor cells confers particular advantages in terms of effectiveness, timing, and ease of use.
Claims18
A method for preparing a pharmaceutical composition containing alloactivated human donor lymphocytes for treating a tumor in a human patient, comprising the steps of:
- a) coculturing the following cells ex vivo:
- lymphocytes from a first human donor allogeneic to the patient, and leukocytes from a second human donor allogeneic to both the first human donor and the patient, so as to alloactivate the lymphocytes;
- and
- b) harvesting the cocultured cells and preparing them for human administration at a time after initiation of the coculturing when the harvested cells, upon implantation in the bed of a solid tumor in the patient, are effective in treating the solid tumor or eliciting an anti-tumor immunological response in the patient.
A method for preparing a cultured cell population containing alloactivated human donor lymphocytes effective in treating a tumor in a human patient, comprising the steps of:
- a) obtaining lymphocytes from a first human donor allogeneic to the patient, and
- b) obtaining leukocytes from a second human donor allogeneic to both the first human donor and the patient;
- c) coculturing the lymphocytes ex vivo with the leukocytes so as to alloactivate the lymphocytes;
- d) harvesting the cocultured cells from culture at a time when the harvested cells, upon implantation in the bed of a solid tumor in the patient, are effective in treating the tumor or eliciting an anti-tumor immunological response;
- e) washing culture medium from the harvested cells;
- and
- f) verifying that the washed cells are sufficiently sterile for human administration.
Dependencies are inferred from the claim text.